With only 70 months left to meet the SDGs, the world faces a stark reality in the fight against AIDS, requiring urgent action ...

Jarunee Siriphan, director at the Foundation for Action on Inclusion Rights (Fair) and founder of the People's Movement to ...

The PETITE study is evaluating two formulations of dolutegravir in newborn babies under 4 weeks of age – an oral film. In the ...

Founded 5 years ago, the Institute of HIV Research and Innovation works with communities to answer the research questions that matter most to them. Sima Barmania reports from Bangkok.

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...

The PETITE-DTG study evaluated dolutegravir (DTG) — a drug that revolutionized HIV treatment in adults and children — in ...

Thailand is working with authorities in the capital cities or embassies of some countries that have citizens stuck on the ...

Nearly half (44%) of all new HIV infections globally in 2023 were in women and girls.1 Adolescent girls and young women are disproportionately affected by HIV, particularly in sub-Saharan Africa where ...

By Gift BritonFor the first time, infants younger than 28 days (neonates) can safely receive Dolutegravir (DTG), one of the most effective and widely used HIV drugs worldwide.Since the World Health ...

Trump’s foreign aid freeze has disrupted HIV treatment programs in South Africa, leaving thousands without life-saving medication and fuelling a growing health crisis.